



**NDA 17-806/S-025**

**SUPPLEMENT APPROVAL**

Lantheus Medical Imaging, Inc.  
Attention: James Williams  
Associate Director, Regulatory Affairs  
331 Treble Cove Road  
North Billerica, MA 01862

Dear Mr. Williams:

Please refer to your Supplemental New Drug Application (sNDA) dated February 25, 2011, received February 28, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Thallous Chloride [Tl-201] Injection.

We acknowledge receipt of your submissions dated April 25, June 21 and August 11, 2011.

Reference is also made to the August 9, 2011, teleconference with Lantheus and FDA, and subsequent Information Request letter dated August 9, 2011.

This "Changes Being Effected" supplemental new drug application provides for the following alterations to the prescribing information:

- A change in the description of the half-life from 73.1 to 72.91, under "Physical Characteristics" and Table 3 in the DESCRIPTION section.
- Deletion of the statement, (b) (4) in the WARNINGS section.
- Addition of the statement, "The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex" in the WARNINGS section.

This application also provides for addition of the following text to the to the vial and carton label: "Vial stopper contains dry natural rubber latex".

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to, except with the revisions indicated, the enclosed labeling (package insert, vial and outer container labels ) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions indicated above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed.

Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Product Correspondence – Final Printed Carton and Container Labels for approved “NDA 17-806/S-025.” Approval of this submission by FDA is not required before the labeling is used.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory

comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have questions, call Ms. Sharon Thomas, Regulatory Project Manager, at (301) 796-1994.

Sincerely,

*{See appended electronic signature page}*

Rafel Rieves, M.D.  
Director  
Division of Medical Imaging Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RAFEL D RIEVES  
08/25/2011